Mifepristone is one of two medicines commonly used for medication abortion, usually with misoprostol. The FDA first approved mifepristone in 2000 and regulates it through REMS, which sets rules for certified prescribers and pharmacies. Under current FDA information, the medicine may be dispensed in person or by mail by certified providers or pharmacies. As of May 5, 2026, a temporary Supreme Court order has kept telehealth, mail, and pharmacy access in place until at least May 11, 2026, while the Court considers emergency requests after a lower-court ruling would have restored an in-person dispensing rule. Federal FDA rules and state abortion laws can point in different directions, so this debate affects patients, doctors, pharmacies, states, and courts. This poll asks about public policy only and does not give medical advice. The question is whether federal policy should keep current access rules, add oversight, defer more to states, or return to older in-person limits while courts review the issue.
What should federal policy do about access to mifepristone while courts review the FDA’s current rules?